Summary
Pfizer receives FDA approval for Vizimpro which treats a rare form of lung cancer.
With the latest FDA approval for Vizimpro, Pfizer now has two drugs that target 3 rare forms of lung cancer expanding the market opportunity.
Pfizer's Vizimpro will not have an easy time penetrating the market because it will have to go up against AstraZeneca's Tagrisso.
Priority Review for FDA approval was made possible because patients treated with Vizimpro obtained a PFS rate of 14.7 months compared to only 9.2 months for those on gefitinib.
Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Get started today »
Recently, Pfizer (PFE) announced that it had received FDA approval for a rare form of lung cancer. The FDA approved a drug known as dacomitinib which will be marketed as Vizimpro. This means the big pharma now has two different drugs that target three indications for rare forms of lung cancer. This approval won't be a blockbuster drug by any means, but it most certainly will start to add up in additional revenue. For that reason, I believe that Pfizer is a buy.
